Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

24/05/2022

B2RLaw as a partner of CEE VC Summit 2022

Together with Vestbee we would like to invite all startups and VC funds for the biggest event dedicated to VC […]

MORE
09/05/2022

B2RLaw commits to Greener Litigation

With a leading, and one of the largest disputes practices in Poland, B2RLaw is the first Polish law firm to […]

MORE
06/05/2022

B2RLaw advises Partners for Growth on multi-million USD international Venture Debt transaction

B2RLaw acted as Polish legal counsel to Partners for Growth (PFG) on its cross-border USD 25 million Venture Debt financing […]

MORE
26/04/2022

B2RLaw advises Fortress REIT on another logistics transaction regarding property in Zabrze

B2RLaw has advised South African-based Fortress REIT Limited on another logistics and warehousing acquisition, regarding property in the Silesia region […]

MORE
12/04/2022

B2RLaw recommended in the Legal500 ranking 2022

We are proud to announce that in this year’s edition of The Legal 500 we have been recommended in 5 […]

MORE
04/04/2022

B2RLaw appoints Piotr Szelenbaum as Partner to lead Capital Markets and Public M&A practices

B2RLaw has appointed well-regarded lawyer Piotr Szelenbaum to lead its Capital Markets and Public M&A practices. Piotr has over 25 […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close